TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features
- PMID: 34001963
- PMCID: PMC8129122
- DOI: 10.1038/s41598-021-89906-w
TERTp mutations and p53 expression in head and neck cutaneous basal cell carcinomas with different aggressive features
Abstract
Cutaneous basal cell carcinoma (cBCC) is an economic burden to health services, due to its great morbidity and increasing incidence in old people. Infiltrative cBCCs and cBCCs with micronodular pattern are considered as more aggressive. The role of p53 expression and TERTp mutation on cBCC behavior remains to be clarified. We aimed to assess TERTp mutations and p53 expression in relation to the cBCC histological subtype in a cohort of patients referred to an ENT Department of a tertiary Hospital of Northern Portugal. We performed a retrospective clinicopathological and histological review of the head and neck cBCCs followed-up at the otorhinolaryngology department of Trás-os-Montes e Alto Douro hospital (January 2007-June 2018). We assessed TERTp mutations in 142 cBCCs and p53 protein expression, through immunohistochemistry, in 157 cBCCs. We detected TERTp mutations in 43.7% of cBCCs and p53 overexpression in 60.5% of cBCCs. We spotted association of p53 overexpression and TERTp mutation with necrosis. In the infitrative-growth pattern cBCCs, there was no significant association with the clinical and histological features evaluated, except for necrosis. In the indolent-growth cBCCs, we identified a significant association of TERTp mutation status with female sex, necrosis, multiple cBCCs, and p53 positive expression. Our results suggest that TERTp mutation may be useful to identify more aggressive features in the indolent-growth pattern cBCCs (nodular and superficial subtypes). Further studies with larger cohorts are warranted to clarify the relevance of TERTp mutation in cBCCs.
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Clinicopathological features of head and neck cutaneous basal cell carcinoma observed at the Centro Hospitalar de Trás-os-Montes e Alto Douro ENT Department.Porto Biomed J. 2022 Oct 24;7(5):e190. doi: 10.1097/j.pbj.0000000000000190. eCollection 2022 Sep-Oct. Porto Biomed J. 2022. PMID: 37213919 Free PMC article.
-
TERT promoter mutation in sebaceous neoplasms.Virchows Arch. 2021 Sep;479(3):551-558. doi: 10.1007/s00428-021-03083-9. Epub 2021 Mar 25. Virchows Arch. 2021. PMID: 33768319
-
TERT promoter mutations are associated with poor prognosis in cutaneous squamous cell carcinoma.J Am Acad Dermatol. 2019 Mar;80(3):660-669.e6. doi: 10.1016/j.jaad.2018.08.032. Epub 2018 Aug 28. J Am Acad Dermatol. 2019. PMID: 30165166
-
Basal cell carcinoma: a dermatopathological and molecular biological update.Br J Dermatol. 2003 Feb;148(2):195-202. doi: 10.1046/j.1365-2133.2003.05151.x. Br J Dermatol. 2003. PMID: 12588368 Review.
-
Head and neck cutaneous basal cell carcinoma: what should the otorhinolaryngology head and neck surgeon care about?Acta Otorhinolaryngol Ital. 2020 Feb;40(1):5-18. doi: 10.14639/0392-100X-2245. Epub 2019 Jul 31. Acta Otorhinolaryngol Ital. 2020. PMID: 31388193 Free PMC article. Review.
Cited by
-
Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma.Int J Mol Sci. 2022 Oct 8;23(19):11968. doi: 10.3390/ijms231911968. Int J Mol Sci. 2022. PMID: 36233269 Free PMC article. Review.
-
Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma.J Immunother Cancer. 2022 May;10(5):e004839. doi: 10.1136/jitc-2022-004839. J Immunother Cancer. 2022. PMID: 35545318 Free PMC article.
References
-
- Lang BM, et al. S2k guidelines for cutaneous basal cell carcinoma-part 1: epidemiology, genetics and diagnosis. JDDG. 2019;17(1):94–103. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous